- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05468203
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care (PREVENTS-AKI)
Background Acute Kidney Injury (AKI) is a potentially life-threatening condition caused by unsafe levels of fluid and waste products accumulating in the body. Often, patients with AKI need treatment with an artificial kidney (called renal replacement therapy or dialysis) to do the work of their kidneys and remove these dangerous levels of fluid and waste from the body. If left untreated, AKI can become a chronic (long-term) condition that may require treatment for life.
Dapagliflozin is a medication used to treat patients with diabetes, heart disease and long-term (chronic) kidney disease. Recently, Dapagliflozin has been shown to slow the progression of other kidney related complications, however this has not yet been studied in critically ill patients.
Aim To determine if giving Dapagliflozin (one tablet a day) compared to placebo (a tablet that looks identical but has no active ingredients), decreases injury to the kidneys in patients admitted to the Intensive Care Unit.
Design This study will enrol 3000 patients from 45-50 hospitals worldwide. It is a 'randomised controlled trial' meaning patients will be randomly assigned (like tossing a coin) by a computer to receive either Dapagliflozin or placebo for a maximum of 30 days whilst in the ICU. The study is also a 'double blinded trial' meaning that neither the doctor, the intensive care staff or the patient will know which study treatment they are receiving.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute kidney injury (AKI) is an increasingly common complication of hospitalisation globally, and a major driver of poor patient outcomes, including higher mortality and reduced quality of life. While numerous studies, including several led by investigators in this grant team, have tested treatments to reduce the impact of AKI, none have been shown to improve outcomes. The absence of any proven therapy highlights a critical unmet need.
A novel class of medicines, inhibitors of the sodium-glucose co-transporter II (SGLT-2 inhibitors), have been shown in recent years to have dramatic effects upon cardiovascular and renal outcomes in patients with heart failure at high risk for renal failure. The evidence suggests that these drugs might prevent AKI from occurring, but this has not been intentionally tested in adequately powered trials. A recently published randomised controlled trial evaluated the use of these drugs in acutely unwell COVID-19 patients and did not raise any safety concern in this acute setting. The trial also showed a numerically lower rate of AKI in those that received the SGLT-2 inhibitor dapagliflozin compared to placebo, but the trial was not sufficiently powered for this outcome.
The PREVENTion with Sglt2 inhibition of Acute Kidney Injury in intensive care (PREVENTS-AKI) trial, will test the effect of dapagliflozin versus placebo upon patients' risk of developing severe AKI in a population admitted to intensive care. This global trial will test the most promising treatment for mitigating the increased risk of AKI. The results will provide the first definitive insight into the prevention of AKI with these agents and will shape global clinical practice in an area where treatments are profoundly lacking.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sarah Coggan, BSc, MPH
- Phone Number: 02 9993 4566
- Email: scoggan@georgeinstitute.org.au
Study Contact Backup
- Name: Sharon Micallef, BN
- Email: smicallef@georgeinstitute.org.au
Study Locations
-
-
Victoria
-
Ballarat, Victoria, Australia, 3350
- Not yet recruiting
- Grampians Health
-
Contact:
- Khaled El-Khawas, Dr
-
Principal Investigator:
- Khaled El-Khawas
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health
-
Contact:
- Rinaldo Bellomo, Prof
-
Principal Investigator:
- Rinaldo Bellomo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or more
- Admitted to ICU within the last 7 days
- Expected to be in the ICU the day after tomorrow
- An arterial or central venous catheter is in situ, or placement is planned for routine management
- Able to receive study treatment orally or via enteral route
At least one of the following risk factors for AKI:
- Required fluid resuscitation, defined as a bolus of fluid prescribed to be given over ≤1 hour to increase or maintain intravascular volume that is in addition to maintenance fluids
- Being treated with continuous vasopressors or inotropes to maintain a systolic blood pressure > 90mmHg, or mean arterial blood pressure > 60mmHg or a MAP target set by the treating clinician for maintaining perfusion
At least one of the following pre-morbid risk factors:
- Treatment for high blood pressure
- Treatment for type 2 diabetes (minimum diet therapy)
- Atherosclerotic cardiovascular disease
- History of heart failure
- Impaired renal function, defined as an eGFR between 20 - 60 mL/min/1.73m2
- Estimated BMI 30 kg/m2 or more
- Age 60 years or more
Exclusion Criteria:
- Met all inclusion criteria more than 24 hours ago
- History of type 1 diabetes mellitus or diabetic ketoacidosis
- COVID-19 infection as the reason for ICU admission
- Requiring renal replacement therapy for intoxication
- eGFR less than 20 mL/min/1.73m2
- Known hypersensitivity to any SGLT-2 inhibitor e.g. dapagliflozin, canagliflozin, empagliflozin, ertugliflozin
- Solid organ transplantation within the last 12 months
- Likely to be transferred to another hospital in the next 3 days
- Known or suspected pregnancy
- Death is deemed imminent or inevitable
- Life expectancy is estimated to be less than 90 days
- Patient or the treating clinician declines to participate
- Enrolled in another interventional trial for which co-enrolment is not approved
- Patient has previously been enrolled in the PREVENTS-AKI Study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin
Dapaliflozin 10mg tablet administered once daily while in ICU for up to 30 days
|
Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Other Names:
|
Placebo Comparator: Matched Placebo
Matched placebo tablet administered once daily while in ICU for up to 30 days
|
Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite outcome: Doubling of serum creatinine from baseline, initiation of renal replacement therapy or death
Time Frame: Within 30 days of randomisation
|
Proportion of patients experiencing a component of the composite outcome, defined as a doubling of serum creatinine from the study baseline value, initiation of RRT or death
|
Within 30 days of randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Doubling of Serum Creatinine
Time Frame: Within 30 days of randomisation
|
Proportion of patients with a doubling of serum creatinine from baseline value
|
Within 30 days of randomisation
|
Requirement of Renal Replacement Therapy (RRT)
Time Frame: Within 30 days of randomisation
|
Proportion of patients requiring RRT
|
Within 30 days of randomisation
|
All-cause mortality
Time Frame: Within 30 days of randomisation
|
Proportion of patients who have died from any cause
|
Within 30 days of randomisation
|
Vasoactive drug therapy
Time Frame: Within 30 days of randomisation
|
Proportion of patients who were treated with vasoactive drugs
|
Within 30 days of randomisation
|
Mechanical ventilation
Time Frame: Within 30 days of randomisation
|
Proportion of patients who required mechanical ventilation
|
Within 30 days of randomisation
|
Ventricular tachycardia or ventricular fibrillation
Time Frame: Within 30 days of randomisation
|
Proportion of patients who experienced ventricular tachycardia or ventricular fibrillation lasting at least 30 seconds whilst in intensive care
|
Within 30 days of randomisation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Martin P Gallagher, MBBS, FRACP, The George Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Wounds and Injuries
- Acute Kidney Injury
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Dapagliflozin
- Sodium-Glucose Transporter 2 Inhibitors
Other Study ID Numbers
- GI-RM-7738
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Ain Shams UniversityRecruiting
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
Clinical Trials on Dapagliflozin 10mg Tab
-
Chinese University of Hong KongRecruitingChronic Hepatitis BHong Kong
-
Region Örebro CountyHarvard Medical School (HMS and HSDM); London School of Hygiene and Tropical... and other collaboratorsNot yet recruitingAtrial Fibrillation | Chronic Coronary Syndrome
-
Seoul National University Bundang HospitalRecruitingDiabetes Type 2Korea, Republic of
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruiting
-
Nidae AlaaRecruitingDiabetic RetinopathyEgypt
-
Nanjing University School of MedicineRecruiting
-
Monaldi HospitalRecruitingEfficacy | Systemic Right Ventricle | Dapagliflozin Adverse ReactionItaly
-
Oman Ministry of HealthNot yet recruitingObesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
-
YangjinPeking University Third HospitalNot yet recruitingPrediabetic State | Impaired Glucose Tolerance | Impaired Fasting GlucoseChina